Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06785012 | A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder | PHASE2 | ACTIVE NOT_RECRUITING | 107 | — | — | Dec 26, 2024 | Jun 26, 2026 | Jun 5, 2026 | 44 | United States |
The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
| Arm | Type | Description |
|---|---|---|
| Arm 1: JNJ-89495120 Dose A | EXPERIMENTAL | Participants will receive JNJ-89495120 dose A during the double-blind (DB) treatment phase in Period 1 and Period 2 of the study. |
| Arm 2: JNJ-89495120 Dose A and Dose B | EXPERIMENTAL | Participants will receive JNJ-89495120 dose A in Period 1 followed by JNJ-89495120 dose B in Period 2 during the DB treatment phase of the study. |
| Arm 3: Placebo Group | PLACEBO_COMPARATOR | Participants will receive placebo matched to JNJ-89495120 during the DB treatment phase in Period 1 and Period 2 of the study. |
| Name | Type | Description |
|---|---|---|
| JNJ-89495120 | DRUG | JNJ-89495120 will be administered. |
| Placebo | DRUG | Placebo will be administered. |
Inclusion Criteria: * Primary psychiatric diagnosis of recurrent major depressive disorder, without psychotic features, based on clinical assessment using diagnostic and statistical manual of mental disorders (DSM)-5 criteria and confirmed with the mini international neuropsychiatric interview (MIN...